Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 IMBRUVICA Capsules Gain Approval in CLL | Contract Pharma

What are you searching for?

Sign in
Breaking News

IMBRUVICA Capsules Gain Approval in CLL

Catalent to provide commercial supply from Kansas City site

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

IMBRUVICA (ibrutinib) has been approved by the FDA as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The drug was originally approved on November 13, 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
 
Catalent Pharma Solutions has been contracted by Pharmacyclics to provide drug product capsules of IMBRUVICA for commercial supply from its site in Kansas City, MO.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics